| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.086 | 0.004 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.005 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.005 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.098 | 0.005 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |